Vahdat-Lasemi F, Farhoudi L, Hosseinikhah SM, Santos RD, Sahebkar A. Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia. Atherosclerosis. 2025 Jun;405:119235.
Singh AK, Chaube B, Zhang X, Sun J, Citrin KM, Canfrán-Duque A, Aryal B, Rotllan N, Varela L, Lee RG, Horvath TL, Price N, Suárez Y, Fernandez-Hernando C. Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice. J Clin Invest. 2021 Jul 13;131(17):e140989.
Chua D, Low ZS, Kim JHS, Lee YH, Kiatbumrung R, Somnark P, Xu M, Shi Y, Kaushal G, Vos MIG, Mahadevan A, Hooi N, Raj M, Sviriaeva E, Cui B, Tan S, Kasahara K, Ho CL, Wahli W, Yew KC, Wong SH, Cheung C, Pal M, Zhang R, Chuaypen N, Tangkijvanich P, Cheng HS, Li L, Tan NS. Angptl4 integrates dietary and microbial signals to disrupt gut barrier function in MASH. Nat Commun. 2026 May 22.
Yin D, Fang N, Zhu Y, Bao X, Yang J, Zhang Q, Wang R, Huang J, Wu Q, Ma F, Wei X. Adipocytes-induced ANGPTL4/KLF4 axis drives glycolysis and metastasis in triple-negative breast cancer. J Exp Clin Cancer Res. 2025 Jul 4;44(1):192.
Janssen AWF, Katiraei S, Bartosinska B, Eberhard D, Willems van Dijk K, Kersten S. Loss of angiopoietin-like 4 (ANGPTL4) in mice with diet-induced obesity uncouples visceral obesity from glucose intolerance partly via the gut microbiota. Diabetologia. 2018 Jun;61(6):1447-1458.